Back to search

Switzerland· 66472001

Maviret Filmtabletten

A glecaprevir and pibrentasvir product containing glecaprevirum, pibrentasvirum, registered in Switzerland by AbbVie AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AP57

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedMaviret FilmtablettenATCJ05AP57REGISTER NO.66472001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Glecaprevir and pibrentasvir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Glecaprevir and pibrentasvir · ATC J05AP57

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
glecaprevirum, pibrentasvirum
Manufacturer
AbbVie AG
Country
Switzerland (CH)
ATC code
J05AP57
ATC class
Glecaprevir and pibrentasvir
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680664720013
    84 Stk
    CHF 13798.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Glecaprevir and pibrentasvir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glecaprevir and pibrentasvir products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
  • Iceland · Maviret
  • Liechtenstein · Maviret
  • Norway · Maviret

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c697c6f9-689d-4378-9801-e2c2110b87c8
GET /v1/drugs/c697c6f9-689d-4378-9801-e2c2110b87c8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "glecaprevirum 100 mg + pibrentasvirum 40 mg",
  "valid_from": "2022-01-01",
  "limitations": "[{\"description\":\"Zur Behandlung der chronischen Hepatitis C (CHC) Genotyp 1‐6 bei Erwachsenen und Jugendlichen ab 12 Jahren.<br>\\nIst eine 12- oder 16‐wöchige Behandlung mit MAVIRET erforderlich, vergütet die AbbVie AG nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, den Fabrikabgabepreis der dritten/vierten, nachweislich verabreichten Packung à je Fr. 13’148.57 zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Betrag zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20698.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\"}]",
  "galenic_form": "Filmtabl 100mg/40mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2017-12-01",
  "self_retention_pct": 10
}

See everything about glecaprevir and pibrentasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.